Key Points
- Insider sale: Mayukh Sukhatme sold 26,831 Roivant shares on Dec. 17 at an average price of $23.09 for proceeds of $619,527.79, trimming his position by 0.14% to 18,869,229 shares (valued at roughly $435.7M).
- Stock snapshot: ROIV opened at $22.41, with a 50‑day/200‑day SMA of $20.00/$15.07, a market cap of $15.59 billion, and a one‑year range of $8.73 to $23.47.
- Ownership and sentiment: Institutional investors hold 64.76% of the shares, and analysts carry a consensus "Moderate Buy" rating with a target price of $25.19.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $23.09, for a total transaction of $619,527.79. Following the sale, the insider directly owned 18,869,229 shares in the company, valued at $435,690,497.61. The trade was a 0.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Roivant Sciences Price Performance
Shares of ROIV opened at $22.41 on Friday. The company has a 50-day simple moving average of $20.00 and a two-hundred day simple moving average of $15.07. The firm has a market capitalization of $15.59 billion, a PE ratio of -40.02 and a beta of 1.22. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $23.47.
Institutional Trading of Roivant Sciences
Institutional investors and hedge funds have recently modified their holdings of the business. Rubric Capital Management LP lifted its holdings in shares of Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock valued at $229,574,000 after purchasing an additional 2,603,260 shares in the last quarter. State Street Corp raised its position in Roivant Sciences by 4.8% in the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company's stock worth $222,847,000 after buying an additional 911,827 shares during the last quarter. Two Seas Capital LP lifted its stake in Roivant Sciences by 4.6% during the 2nd quarter. Two Seas Capital LP now owns 10,598,040 shares of the company's stock valued at $119,440,000 after acquiring an additional 461,733 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Roivant Sciences by 18.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company's stock valued at $140,839,000 after acquiring an additional 1,423,074 shares during the last quarter. Finally, BlackBarn Capital Partners LP grew its stake in shares of Roivant Sciences by 15.2% in the first quarter. BlackBarn Capital Partners LP now owns 4,750,000 shares of the company's stock worth $47,928,000 after acquiring an additional 625,000 shares during the period. Institutional investors own 64.76% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the company. Bank of America increased their price objective on Roivant Sciences from $12.00 to $16.50 and gave the stock a "neutral" rating in a report on Thursday, September 18th. Leerink Partners raised their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday. Guggenheim restated a "buy" rating and issued a $28.00 price target on shares of Roivant Sciences in a research note on Thursday. Weiss Ratings upgraded Roivant Sciences from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Saturday, October 25th. Finally, JPMorgan Chase & Co. increased their target price on Roivant Sciences from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $25.19.
Read Our Latest Stock Report on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
